ArticleJCO precision oncology2026
Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTranslocation-associated sarcomas (TAS) represent a heterogeneous group of pathologic entities characterized by specific gene fusions and a low tumor mutational burden (TMB). Although RNA sequencing remains the hallmark molecular platform to establish the fusion type, targeted panel DNA next-generation sequencing (NGS) has been increasingly used in TAS to identify actionable alterations as well as potential mechanisms of resistance to therapy. MATERIALS AND
methodsWe herein investigate sequential targeted DNA sequencing (Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling of Actionable Cancer Targets) in a large cohort of 108 TAS, spanning six most common subtypes, with available longitudinal sequencing.
resultsOverall, 53% of cases acquired alterations (n = 122) compared with the initial testing, of which 33 (27%) were oncogenic/likely oncogenic. Only two of the five patients with >3 tests/each acquired oncogenic mutations. Overall, 21% of cases did not acquire alterations in any assay. Subsequent NGS was initiated after systemic treatment (93%) and disease progression (83%). The number of oncogenic acquired alterations did not correlate with histotype (mean 0.4/case). In sequential NGS, the mean mutation count, TMB, and fraction of genome altered were significantly higher (
conclusionThe role of multiple NGS testing in the context of TAS remains undetermined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.